TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Open-Label, Phase II Study Assessing the Efficacy and the Safety of Bevacizumab in Neoadjuvant Therapy in Patients With FIGO Stage IIIC/IV Ovarian, Tubal or Peritoneal Adenocarcinoma, Initially Unresectable
Brief Summary: This randomized, open-label study will evaluate the efficacy and safety of neoadjuvant bevacizumab in participants with initially unresectable, FIGO stage IIIC/IV ovarian, tubal, or peritoneal cancer. Participants will be randomized to receive 8 cycles of carboplatin plus paclitaxel with or without bevacizumab before surgery (interval debulking surgery \[IDS\]). Surgery will be scheduled 28 days after the last course of neoadjuvant treatment in participants with resectable cancer. Participants with unresectable cancer will go through the follow-up period. All participants will receive bevacizumab for Cycles 6 to 26.


Options:
A: Arm Label: Arm I (bevacizumab and everolimus); Type: EXPERIMENTAL; Interventions: Biological: Bevacizumab, Drug: Everolimus, Other: Laboratory Biomarker Analysis | Arm Label: Arm II (bevacizumab and placebo); Type: EXPERIMENTAL; Interventions: Biological: Bevacizumab, Other: Laboratory Biomarker Analysis, Other: Placebo | Intervention Type: BIOLOGICAL; Name: Bevacizumab; Assigned to Arm(s): Arm I (bevacizumab and everolimus), Arm II (bevacizumab and placebo) | Intervention Type: DRUG; Name: Everolimus; Assigned to Arm(s): Arm I (bevacizumab and everolimus) | Intervention Type: OTHER; Name: Laboratory Biomarker Analysis; Assigned to Arm(s): Arm I (bevacizumab and everolimus), Arm II (bevacizumab and placebo) | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Arm II (bevacizumab and placebo)
B: Arm Label: BIBF1120; Type: EXPERIMENTAL; Interventions: Drug: BIBF1120 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: BIBF1120; Assigned to Arm(s): BIBF1120 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Carboplatin + Paclitaxel + Bevacizumab; Type: EXPERIMENTAL; Interventions: Drug: Carboplatin, Drug: Paclitaxel, Drug: Bevacizumab | Arm Label: Carboplatin + Paclitaxel; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carboplatin, Drug: Paclitaxel, Drug: Bevacizumab | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Carboplatin + Paclitaxel, Carboplatin + Paclitaxel + Bevacizumab | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Carboplatin + Paclitaxel, Carboplatin + Paclitaxel + Bevacizumab | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Carboplatin + Paclitaxel, Carboplatin + Paclitaxel + Bevacizumab
D: Arm Label: PLD; Type: ACTIVE_COMPARATOR; Interventions: Drug: PLD 40mg/m2 ivgtt q4w | Arm Label: PLD + Apatinib; Type: EXPERIMENTAL; Interventions: Drug: PLD 40mg/m2 ivgtt q4w +Apatinib 250mg po qd | Intervention Type: DRUG; Name: PLD 40mg/m2 ivgtt q4w +Apatinib 250mg po qd; Assigned to Arm(s): PLD + Apatinib | Intervention Type: DRUG; Name: PLD 40mg/m2 ivgtt q4w; Assigned to Arm(s): PLD

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Collaborative Care to Alleviate Symptoms and Adjust to Illness in Chronic Heart Failure (CASA) Trial
Brief Summary: Chronic heart failure is an important public health problem as it is a leading cause of disability, hospitalization, death, and costs. People who live with advanced chronic heart failure suffer from numerous symptoms that affect their daily lives. The investigators are conducting a randomized clinical trial to evaluate a symptom management and psychosocial care intervention to improve health status (symptom burden, functioning, and quality of life). The results will be directly relevant to patients and families who suffer with this illness, as well as to providers, payers, and other researchers.


Options:
A: Arm Label: CASA Intervention; Type: EXPERIMENTAL; Interventions: Other: CASA Intervention | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: CASA Intervention; Assigned to Arm(s): CASA Intervention
B: Arm Label: Internet-based CBT; Type: EXPERIMENTAL; Interventions: Behavioral: Internet-based CBT | Arm Label: Treatment as usual (TAU); Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Internet-based CBT; Assigned to Arm(s): Internet-based CBT
C: Arm Label: Intervention Condition (INT); Type: EXPERIMENTAL; Interventions: Behavioral: Enhanced depression care | Arm Label: Usual Cardiologic Care Condition (UCC); Type: OTHER; Interventions: Behavioral: Referred depression care | Intervention Type: BEHAVIORAL; Name: Enhanced depression care; Assigned to Arm(s): Intervention Condition (INT) | Intervention Type: BEHAVIORAL; Name: Referred depression care; Assigned to Arm(s): Usual Cardiologic Care Condition (UCC)
D: Arm Label: Sertraline/omega-3 supplement; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sertraline/omega-3 | Arm Label: Sertraline/corn oil; Type: PLACEBO_COMPARATOR; Interventions: Drug: Sertraline/Corn Oil | Intervention Type: DRUG; Name: Sertraline/omega-3; Assigned to Arm(s): Sertraline/omega-3 supplement | Intervention Type: DRUG; Name: Sertraline/Corn Oil; Assigned to Arm(s): Sertraline/corn oil

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase 1 Randomized-Double Blind Clinical Trial of Intravenous Infusion of Umbilical Cord Mesenchymal Stem Cells Transplantation in Heart Failure on Patients With Cardiopathy in Dilated Stage, of Different Etiology
Brief Summary: The purpose of this study is to determine the safety and clinical effectiveness of umbilical cord mesenchymal cells transplanted by intravenous infusion in patients with heart failure.


Options:
A: Intervention Type: PROCEDURE; Name: Intramyocardial injection of autologous bone marrow cells; Assigned to Arm(s): N/A
B: Arm Label: Provacel: Cohort 1; Type: ACTIVE_COMPARATOR; Interventions: Biological: Provacel | Arm Label: Provacel: Cohort 2; Type: ACTIVE_COMPARATOR; Interventions: Biological: Provacel | Arm Label: Provacel: Cohort 3; Type: ACTIVE_COMPARATOR; Interventions: Biological: Provacel | Arm Label: Provacel: Cohort 4; Type: ACTIVE_COMPARATOR; Interventions: Biological: Provacel | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: Provacel; Assigned to Arm(s): Provacel: Cohort 1, Provacel: Cohort 2, Provacel: Cohort 3, Provacel: Cohort 4 | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Biological: C-Cure | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BIOLOGICAL; Name: C-Cure; Assigned to Arm(s): 1
D: Arm Label: ucMSC; Type: EXPERIMENTAL; Interventions: Biological: ucMSC | Arm Label: Controls; Type: PLACEBO_COMPARATOR; Interventions: Other: Controls | Intervention Type: BIOLOGICAL; Name: ucMSC; Assigned to Arm(s): ucMSC | Intervention Type: OTHER; Name: Controls; Assigned to Arm(s): Controls

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Polymedication Check - Evaluation of the Impact of Community Pharmacy Based Medication Review on Medicines Use and Humanistic Outcomes
Brief Summary: Since October 2010, Swiss community pharmacies can offer a 'Polymedication Check' (PMC) to patients on ≥4 prescribed drugs taken over ≥3 months.

Aims:

To evaluate first experiences shortly after implementation, missed pharmaceutical care issues and barriers to implementation on pharmacist's level as well as patient's acceptance through qualitative and descriptive studies To evaluate the impact of PMC in Swiss primary Care and to evaluate economic, clinical and humanistic outcomes in a subsequent randomized controlled trial.


Options:
A: Arm Label: Medication therapy management; Type: EXPERIMENTAL; Interventions: Other: Medication therapy management | Intervention Type: OTHER; Name: Medication therapy management; Assigned to Arm(s): Medication therapy management
B: Arm Label: Reciprocal Diabetes Peer Support program; Type: EXPERIMENTAL; Interventions: Behavioral: Reciprocal Diabetes Peer Support Program, Behavioral: group outpatient counseling visits | Arm Label: Nurse Case Management; Type: OTHER; Interventions: Behavioral: Nurse Case management | Intervention Type: BEHAVIORAL; Name: Reciprocal Diabetes Peer Support Program; Assigned to Arm(s): Reciprocal Diabetes Peer Support program | Intervention Type: BEHAVIORAL; Name: Nurse Case management; Assigned to Arm(s): Nurse Case Management | Intervention Type: BEHAVIORAL; Name: group outpatient counseling visits; Assigned to Arm(s): Reciprocal Diabetes Peer Support program
C: Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Medication review | Arm Label: Observational arm; Type: OTHER; Interventions: Behavioral: Medication review | Intervention Type: BEHAVIORAL; Name: Medication review; Assigned to Arm(s): Intervention group, Observational arm
D: Arm Label: Standard Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Diabetes Peer Counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Diabetes Peer Counseling | Intervention Type: BEHAVIORAL; Name: Diabetes Peer Counseling; Assigned to Arm(s): Diabetes Peer Counseling

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Polymedication Check - Evaluation of the Impact of Community Pharmacy Based Medication Review on Medicines Use and Humanistic Outcomes
Brief Summary: Since October 2010, Swiss community pharmacies can offer a 'Polymedication Check' (PMC) to patients on ≥4 prescribed drugs taken over ≥3 months.

Aims:

To evaluate first experiences shortly after implementation, missed pharmaceutical care issues and barriers to implementation on pharmacist's level as well as patient's acceptance through qualitative and descriptive studies To evaluate the impact of PMC in Swiss primary Care and to evaluate economic, clinical and humanistic outcomes in a subsequent randomized controlled trial.


Options:
A: Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Medication review | Arm Label: Observational arm; Type: OTHER; Interventions: Behavioral: Medication review | Intervention Type: BEHAVIORAL; Name: Medication review; Assigned to Arm(s): Intervention group, Observational arm
B: Arm Label: Optimization of drug prescribing; Type: EXPERIMENTAL; Interventions: Other: Optimization of drug prescribing | Arm Label: No intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Optimization of drug prescribing; Assigned to Arm(s): Optimization of drug prescribing
C: Arm Label: Intervention; Type: OTHER; Interventions: Other: E-learning | Arm Label: Control; Type: OTHER; Interventions: Other: E-learning | Intervention Type: OTHER; Name: E-learning; Assigned to Arm(s): Control, Intervention
D: Arm Label: care as usual; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Implementation of Dementia Care Manager; Type: EXPERIMENTAL; Interventions: Other: Implementation of Dementia Care Manager | Intervention Type: OTHER; Name: Implementation of Dementia Care Manager; Assigned to Arm(s): Implementation of Dementia Care Manager

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Feasibility Study of Intraperitoneal Paclitaxel With Oxaliplatin and Capecitabine in Patients With Advanced Gastric Cancer
Brief Summary: This is a single arm phase 2 trial evaluating the efficacy and tolerability of intraperitoneal paclitaxel with oxaliplatin and capecitabine in advanced gastric cancer patients with peritoneal metastasis and/or cancer cells on peritoneal cytology. Twenty patients will be recruited into the study for an estimated period of two years. Paclitaxel will be administered intraperitoneally at 40mg/m2 on Day 1 and 8 in patients receiving standard intravenous oxaliplatin 130mg/m2 on Day 1 and capecitabine 1000mg/m2 on day 1-14. The study hypothesizes that the addition of intraperitoneal paclitaxel with chemotherapy will improve treatment efficacy.


Options:
A: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: S-1/Cisplatin | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: 5-FU/cisplatin | Intervention Type: DRUG; Name: S-1/Cisplatin; Assigned to Arm(s): A | Intervention Type: DRUG; Name: 5-FU/cisplatin; Assigned to Arm(s): B
B: Arm Label: Trastuzumab emtansine; Type: EXPERIMENTAL; Interventions: Drug: Trastuzumab emtansine | Arm Label: Lapatinib + Capecitabine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lapatinib, Drug: Capecitabine | Intervention Type: DRUG; Name: Trastuzumab emtansine; Assigned to Arm(s): Trastuzumab emtansine | Intervention Type: DRUG; Name: Lapatinib; Assigned to Arm(s): Lapatinib + Capecitabine | Intervention Type: DRUG; Name: Capecitabine; Assigned to Arm(s): Lapatinib + Capecitabine
C: Arm Label: IP Paclitaxel; Type: EXPERIMENTAL; Interventions: Drug: IP Paclitaxel | Intervention Type: DRUG; Name: IP Paclitaxel; Assigned to Arm(s): IP Paclitaxel
D: Arm Label: ECX; Type: EXPERIMENTAL; Interventions: Drug: Epirubicin, Drug: Cisplatin, capecitabine | Arm Label: CX; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cisplatin, capecitabine | Intervention Type: DRUG; Name: Epirubicin; Assigned to Arm(s): ECX | Intervention Type: DRUG; Name: Cisplatin, capecitabine; Assigned to Arm(s): CX, ECX

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Altering Sedation Paradigms to Improve Brain Injury and Survival in Severe Sepsis
Brief Summary: Ventilated ICU patients frequently have sepsis and the majority have delirium, a form of brain dysfunction that is an independent predictor of increased risk of dying, length of stay, costs, and prolonged cognitive impairment in survivors. Universally prescribed sedative medications-the GABA-ergic benzodiazepines-worsen this brain organ dysfunction. The available alternative sedation regimens, the shorter acting GABA-ergic propofol, and the alpha2 agonist, dexmedetomidine, have both been shown to be superior to benzodiazepines, and yet are different with regard to their effects on innate immunity, bacterial clearance, apoptosis, cognition and delirium. The MENDS2 study will compare propofol and dexmedetomidine, and determine the best sedative medication to reduce delirium and improve survival and long-term brain function in our most vulnerable patients- the ventilated septic patient.


Options:
A: Arm Label: delirious patients; Type: N/A; Interventions: N/A | Arm Label: non-delirious patients; Type: N/A; Interventions: N/A
B: Arm Label: delirious patients; Type: N/A; Interventions: N/A | Arm Label: non-delirious patients; Type: N/A; Interventions: N/A
C: Arm Label: Dexmedetomidine; Type: EXPERIMENTAL; Interventions: Drug: Dexmedetomidine HCL Injection | Arm Label: Midazolam; Type: ACTIVE_COMPARATOR; Interventions: Drug: Midazolam Injection | Intervention Type: DRUG; Name: Dexmedetomidine HCL Injection; Assigned to Arm(s): Dexmedetomidine | Intervention Type: DRUG; Name: Midazolam Injection; Assigned to Arm(s): Midazolam
D: Arm Label: Dexmedetomidine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dexmedetomidine | Arm Label: Propofol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Propofol | Intervention Type: DRUG; Name: Dexmedetomidine; Assigned to Arm(s): Dexmedetomidine | Intervention Type: DRUG; Name: Propofol; Assigned to Arm(s): Propofol

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: EVALUATION OF THE PILLCAM™ COLON CAPSULE ENDOSCOPY (PCCE) IN PEDIATRIC ULCERATIVE COLITIS
Brief Summary: This prospective pilot study of 30 pediatric subjects, that are indicated for standard colonoscopy due to follow-up of ulcerative colitis (UC), examines the Given Diagnostic System and the PillCam Colon Capsule in comparison to standard colonoscopy.

This study aims

1. To evaluate and compare the accuracy of PillCam ™ Colon capsule endoscopy (PCCE) with standard colonoscopy in the evaluation of colon in pediatric ulcerative colitis.
2. To evaluate the safety of PillCam ™ Colon capsule endoscopy (PCCE) in pediatric age.


Options:
A: Arm Label: 30 children with UC; Type: N/A; Interventions: N/A
B: Intervention Type: DRUG; Name: mesalazine; Assigned to Arm(s): N/A
C: Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Biological: sterile saline for injection | Arm Label: 1; Type: EXPERIMENTAL; Interventions: Biological: MDX-1100 | Intervention Type: BIOLOGICAL; Name: sterile saline for injection; Assigned to Arm(s): 2 | Intervention Type: BIOLOGICAL; Name: MDX-1100; Assigned to Arm(s): 1
D: Arm Label: PLC Colon release tablet 1 g; Type: EXPERIMENTAL; Interventions: Drug: Propionyl-L-Carnitine, Drug: Placebo | Arm Label: PLC colon release tablet 2 g; Type: EXPERIMENTAL; Interventions: Drug: Propionyl-L-Carnitine, Drug: Placebo | Arm Label: Placebo PLC colon release tablet 2 g; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Propionyl-L-Carnitine; Assigned to Arm(s): PLC Colon release tablet 1 g | Intervention Type: DRUG; Name: Propionyl-L-Carnitine; Assigned to Arm(s): PLC colon release tablet 2 g | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): PLC Colon release tablet 1 g, PLC colon release tablet 2 g, Placebo PLC colon release tablet 2 g

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Perioperative Selective Decontamination of the Digestive Tract (SDD) in Elective Colorectal Cancer Patients: a Multicenter Randomized Clinical Trial
Brief Summary: The primary objectives of this randomized clinical trial are to evaluate if perioperative SDD can reduce clinical anastomotic leakage rate and its septic consequences as well as other infectious complications. By reduction of septic complications long-term oncological outcome might simultaneously improve.


Options:
A: Arm Label: Bowel Preparation plus antibiotics; Type: ACTIVE_COMPARATOR; Interventions: Other: Bowel Preparation plus antibiotics | Arm Label: Bowel Preparation; Type: OTHER; Interventions: Other: Bowel Preparation | Intervention Type: OTHER; Name: Bowel Preparation plus antibiotics; Assigned to Arm(s): Bowel Preparation plus antibiotics | Intervention Type: OTHER; Name: Bowel Preparation; Assigned to Arm(s): Bowel Preparation
B: Arm Label: Standard treatment; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Selective decontamination of the digestive tract (SDD); Type: EXPERIMENTAL; Interventions: Drug: Selective decontamination of the digestive tract (SDD) (colistin sulfate, tobramycin, amphotericin B) | Intervention Type: DRUG; Name: Selective decontamination of the digestive tract (SDD) (colistin sulfate, tobramycin, amphotericin B); Assigned to Arm(s): Selective decontamination of the digestive tract (SDD)
C: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: standard operating management | Intervention Type: PROCEDURE; Name: standard operating management; Assigned to Arm(s): 2
D: Arm Label: oral antibiotics+mechanical bowel preparation; Type: EXPERIMENTAL; Interventions: Drug: Neomycin,metronidazole | Arm Label: simple mechanical bowel preparation; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Neomycin,metronidazole; Assigned to Arm(s): oral antibiotics+mechanical bowel preparation

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: The investigators aimed to compare the efficacy of nasal intermittent mandatory ventilation (IMV) and nasal continuous positive airway pressure (CPAP) in early rescue surfactant treatment in preterm infants.


Options:
A: Arm Label: Nasal Continuous Positive Airway Pressure (CPAP); Type: ACTIVE_COMPARATOR; Interventions: Device: Nasal CPAP (SLE) | Arm Label: Nasal Intermittent Mandatory Ventilation (IMV); Type: ACTIVE_COMPARATOR; Interventions: Device: Nasal IMV (SLE) | Intervention Type: DEVICE; Name: Nasal CPAP (SLE); Assigned to Arm(s): Nasal Continuous Positive Airway Pressure (CPAP) | Intervention Type: DEVICE; Name: Nasal IMV (SLE); Assigned to Arm(s): Nasal Intermittent Mandatory Ventilation (IMV)
B: Arm Label: NAVA-PS; Type: EXPERIMENTAL; Interventions: Device: noninvasive respiratory support with NAVA mode and PSV | Arm Label: PS-NAVA; Type: EXPERIMENTAL; Interventions: Device: noninvasive respiratory support with NAVA mode and PSV | Intervention Type: DEVICE; Name: noninvasive respiratory support with NAVA mode and PSV; Assigned to Arm(s): NAVA-PS, PS-NAVA
C: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Device: NIPPV | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Device: nCPAP | Intervention Type: DEVICE; Name: nCPAP; Assigned to Arm(s): B | Intervention Type: DEVICE; Name: NIPPV; Assigned to Arm(s): A
D: Arm Label: NIMV- nasal respiratory support; Type: EXPERIMENTAL; Interventions: Device: NIMV with SLE ventilator vs HFNC via Vapotherm | Arm Label: HFNC- nasal respiratory support with HFNC; Type: EXPERIMENTAL; Interventions: Device: NIMV with SLE ventilator vs HFNC via Vapotherm | Intervention Type: DEVICE; Name: NIMV with SLE ventilator vs HFNC via Vapotherm; Assigned to Arm(s): HFNC- nasal respiratory support with HFNC, NIMV- nasal respiratory support

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: The investigators aimed to compare the efficacy of nasal intermittent mandatory ventilation (IMV) and nasal continuous positive airway pressure (CPAP) in early rescue surfactant treatment in preterm infants.


Options:
A: Arm Label: CPAP ventilation mode; Type: ACTIVE_COMPARATOR; Interventions: Procedure: CPAP ventilation mode | Arm Label: NIPPV ventilation mode; Type: EXPERIMENTAL; Interventions: Procedure: NIPPV ventilation mode | Intervention Type: PROCEDURE; Name: CPAP ventilation mode; Assigned to Arm(s): CPAP ventilation mode | Intervention Type: PROCEDURE; Name: NIPPV ventilation mode; Assigned to Arm(s): NIPPV ventilation mode
B: Arm Label: NAVA-PS; Type: EXPERIMENTAL; Interventions: Device: noninvasive respiratory support with NAVA mode and PSV | Arm Label: PS-NAVA; Type: EXPERIMENTAL; Interventions: Device: noninvasive respiratory support with NAVA mode and PSV | Intervention Type: DEVICE; Name: noninvasive respiratory support with NAVA mode and PSV; Assigned to Arm(s): NAVA-PS, PS-NAVA
C: Arm Label: BP-NCPAP; Type: ACTIVE_COMPARATOR; Interventions: Device: BP-NCPAP | Arm Label: NIHFV; Type: EXPERIMENTAL; Interventions: Device: NIHFV | Intervention Type: DEVICE; Name: BP-NCPAP; Assigned to Arm(s): BP-NCPAP | Intervention Type: DEVICE; Name: NIHFV; Assigned to Arm(s): NIHFV
D: Arm Label: Nasal Continuous Positive Airway Pressure (CPAP); Type: ACTIVE_COMPARATOR; Interventions: Device: Nasal CPAP (SLE) | Arm Label: Nasal Intermittent Mandatory Ventilation (IMV); Type: ACTIVE_COMPARATOR; Interventions: Device: Nasal IMV (SLE) | Intervention Type: DEVICE; Name: Nasal CPAP (SLE); Assigned to Arm(s): Nasal Continuous Positive Airway Pressure (CPAP) | Intervention Type: DEVICE; Name: Nasal IMV (SLE); Assigned to Arm(s): Nasal Intermittent Mandatory Ventilation (IMV)

Answer: D